ClinicalTrials.gg
CompletedNCT06469151Updated Nov 10, 2025

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

A Phase 1 interventional study of AZD5148 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 121 studies in Clostridium Infections with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Clostridium Infections · United States.

Enrollment
42nd of 102
84 · median 57
Started
2024
with 6 others
Phase 1
18 of 121
5 open now
Registered
108th of 121
by date
Lead sponsor
3 of 121
AstraZeneca

Among the 121 studies in Clostridium Infections with a site in United States, this one is the 42nd largest by enrollment of the 102 interventional ones that give a count, is one of 7 that started in 2024, is one of 18 in phase 1, and was the 108th registered.

Clostridium Infections

251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.

Browse Clostridium Infections studies →

Open to participants now

16 of the 121 studies in Clostridium Infections with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Clostridium Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants

Read the detailed description

This is a first in human study which will be conducted at four clinical units. Participants will be randomized to receive AZD5148, or placebo administered by intramuscular (IM) injection into the lateral thigh muscle or intravenous (IV) bolus (single, discrete dose of a drug).

This study will include 7 dose cohorts, two of which will include exclusively participants of Chinese descent, Cohort 2b and 4b. Each dose cohort will begin with a Sentinel Group of 2 participants randomized 1:1 (AZD5148:placebo). The participants in the Sentinel Group will undergo a safety monitoring period of 24 hours before the remaining participants in that cohort are dosed. If there would be no safety concerns, the remaining participants in the cohort will be dosed in a 9:1 ratio (AZD5148: placebo). Each participant will be involved in the study for up to 56 weeks (including Screening Period)

The study will comprise:

  • A Screening Period of maximum 28 days (Day -28 to Day -1 inclusive).
  • A Treatment and Follow-up Period lasting 12 months after the administration of the study drug.

    • Participants will be resident at the Clinical Unit from the day before study drug administration (Day -1) until all assessments are completed on Day 2.
    • A final Follow-up Visit will occur within 361 ± 14 days after the study drug administration.
03

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Clostridioides difficile infection (CDI)
  • Placebo-controlled
  • Anti-drug antibodies (ADA)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants with suitable veins for cannulation or repeated venipuncture at the time of consent.
  • All women must have a negative serum pregnancy test at the Screening Visit.
  • Women of must have a negative urine pregnancy test on admission to the Clinical Unit.
  • Women of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective , to avoid pregnancy from 3 months prior to administration of the study drug and until 360 days after the dose of the study drug.
  • Women of non-childbearing potential must be confirmed at the Screening Visit by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and follicular stimulating hormone (FSH) levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by complete hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.
  • Have a ≥ 18.0 to ≤ 32.0 kg/m2 and weigh ≥ 45 kg and ≤ 110 kg.
  • Willing and able to complete the Follow-up Period through Day 361.
  • Healthy Chinese participants - participants of Chinese descent are eligible based on meeting all of the following specific criteria for these two cohorts (Cohorts 2b and 4b):

    1. Participant with Chinese ancestry, born in mainland China, Hong Kong, or Taiwan.
    2. Participant is the descendant of 4 ethnic Chinese grandparents and 2 ethnic Chinese parents.
    3. Participant has lived outside China for ≤ 10 years at the time of Screening.
    4. Exhibits no significant change in lifestyle, including diet, since leaving China.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study drug.
  • History of other than treated non-melanoma skin cancers or locally treated cervical cancer in previous 5 years.
  • Any medical history of symptomatic CDI within the prior 2 years.
  • Any clinically important abnormalities in laboratory values, vital signs, clinical chemistry, hematology, or urinalysis results.
  • Any positive result on Screening for serum surface antigen (HBsAg) or virus (HCV).
  • Primary or acquired immunodeficiency, including infection or due to drugs, including any course of therapy exceeding 2 weeks of prednisone or equivalent within 6 months prior to Screening. Human immunodeficiency virus (HIV) testing must be negative at Screening Visit.
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead , at Screening.
  • Known or suspected history of alcohol or drug abuse within the past 2 years that might affect assessments of safety or ability of participant to comply with all study requirements.
  • Positive screen for drugs of abuse, or alcohol at Screening or Day -1.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class to the study drug.
  • History of previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).
  • Previous receipt of a mAb within 6 months, or 5 antibody half-lives (whichever is longer), prior to the start of the study.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  • Receipt of immunoglobulin or blood products, or expected receipt, within 6 months prior to Screening or expected to receive during the study.
  • Clinically significant bleeding disorder (e.g., factor VIII deficiency, coagulopathy, or disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
  • Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Cohort 1: AZD5148 (dose 1) IM

    Participants will receive AZD5148 (dose 1) or matching placebo as an IM injection

    Drug: AZD5148 · Drug: Placebo

  • Experimental
    Cohort 2a: AZD5148 (dose 2) IM

    Participants will receive AZD5148 (dose 2) or matching placebo as an IM injection

    Drug: AZD5148 · Drug: Placebo

  • Experimental
    Cohort 2b: AZD5148 (dose 2) IM

    Participants of Chinese descent will receive AZD5148 (dose 2) or matching placebo as an IM injection

    Drug: AZD5148 · Drug: Placebo

  • Experimental
    Cohort 3: AZD5148 (dose 2) IV

    Participants will receive AZD5148 (dose 2) or matching placebo as an IV bolus

    Drug: AZD5148 · Drug: Placebo

  • Experimental
    Cohort 4a: AZD5148 (dose 3) IV

    Participants will receive AZD5148 (dose 3) or matching placebo as an IV bolus

    Drug: AZD5148 · Drug: Placebo

  • Experimental
    Cohort 4b: AZD5148 (dose 3) IV

    Participants of Chinese descent will receive AZD5148 (dose 3) or matching placebo as an IV bolus

    Drug: AZD5148 · Drug: Placebo

  • Experimental
    Cohort 5: AZD5148 (dose 4) IV

    Participants will receive AZD5148 (dose 4) or matching placebo as an IV bolus

    Drug: AZD5148 · Drug: Placebo

Interventions

  • Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus

  • DrugPlacebo

    Participants will receive matching doses of placebo as an IM injection or IV bolus

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs).

    To evaluate the safety and tolerability of AZD5148 administered as a single IV or IM dose to healthy adult participants.

    Time frame: From Day -1 to Day 91

  2. Number of participants with serious adverse events (SAEs) and adverse events of special interest (AESIs)

    To evaluate the safety and tolerability of AZD5148 administered as a single IV or IM dose to healthy adult participants.

    Time frame: From Screening (Day -28 to Day -1) to final Follow-up Visit (Day 361 ± 14)

Secondary outcomes

  1. Maximum observed drug concentration (Cmax)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  2. Time to reach maximum observed concentration (tmax)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  3. Time of last quantifiable concentration (tlast)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  4. Terminal elimination half-life, estimated as (ln2)/λz (t1/2λz)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  5. Area under concentration-curve from time 0 to the time of last quantifiable concentration (AUClast)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  6. Area under concentration-time curve from time 0 extrapolated to infinity (AUCinf)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  7. Volume of distribution at steady state (IV administration only) (Vss)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  8. Volume of distribution at terminal phase (IV administration only) (Vz)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  9. Systematic clearance (IV administration only) (CL)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  10. Apparent total body clearance (IM administration only) (CL/F)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  11. Apparent volume of distribution based on the terminal phase (IM administration only) (Vz/F)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  12. Bioavailability for extravascular administration (IM administration only) (F)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 ± 14 days)

  13. Incidence of positive ADAs against AZD5148 in serum

    To evaluate the ADA responses to a single IV or IM dose of AZD5148.

    Time frame: Day 1 (pre-dose), Day 29, Day 91, Day 181 and Day 361

07

Study locations

4 sites
  • Research Site
    Anniston, Alabama 36207, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Baltimore, Maryland 21225, United States
  • Research Site
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Oct 2025, 15 months.

Of 14 phase 1 interventional studies under Clostridium Infections, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 21, 2024
StartActual
Jun 24, 2024
Primary completionActual
Oct 22, 2025
CompletionActual
Oct 22, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06469151
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Jun 24, 2024
Primary completion
Oct 22, 2025
Completion
Oct 22, 2025
Last update
Nov 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ombetoxabart

Start the discussion